Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2024

This “Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Heart Failure With Reduced Ejection Fraction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Heart Failure With Reduced Ejection Fraction Understanding

Heart Failure With Reduced Ejection Fraction (HFrEF): Overview

Heart failure is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ventricular filling or ejection of blood or both. HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodeling. Assessment for heart failure begins with obtaining a medical history and physical examination. Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thresholds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measured by echocardiography. Treatment strategies include the use of diuretics to relieve symptoms and application of an expanding armamentarium of disease-modifying drug and device therapies. Unless there are specific contraindications, patients with HFrEF should be treated with a ß-blocker and one of an angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, with addition of a mineralocorticoid receptor antagonist in patients with persistent symptoms. Ivabradine and hydralazine/isosorbide dinitrate also have a role in the care of certain patients with HFrEF. More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF.

Heart Failure With Reduced Ejection Fraction - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure With Reduced Ejection Fraction pipeline landscape is provided which includes the disease overview and Heart Failure With Reduced Ejection Fraction treatment guidelines. The assessment part of the report embraces, in depth Heart Failure With Reduced Ejection Fraction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure With Reduced Ejection Fraction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure With Reduced Ejection Fraction R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure With Reduced Ejection Fraction.

Heart Failure With Reduced Ejection Fraction Emerging Drugs Chapters

This segment of the Heart Failure With Reduced Ejection Fraction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart Failure With Reduced Ejection Fraction Emerging Drugs

IONIS-AGT-LRx: Ionis PharmaceuticalsIONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of liver-derived angiotensinogen (AGT), a central component of the renin-angiotensin-aldosterone system (RAAS). Inhibition of the RAAS pathway is a well-established therapeutic approach for treating patients with heart failure (HF). While RAAS pathway blockers, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), are part of the standard of care, their use as monotherapy may result in incomplete RAAS blockade. However, two or more RAAS pathway blockers are not recommended, due to the negative side effects in the kidneys and risk of hypotension.

By targeting AGT, which lies furthest upstream in the RAAS pathway, IONIS-AGT-LRx has the potential to achieve a more complete blockade of the RAAS axis compared to ACE inhibitors and ARBs. Furthermore, the selective inhibition of AGT in the liver may provide a better safety profile by avoiding the kidney side effects seen with the current RAAS inhibitors, which is especially important for patients with chronic kidney dysfunction.

Omecamtiv mecarbil: CytokineticsCytokinetics is developing omecamtiv mecarbil, a novel, selective cardiac myosin activator for the potential treatment for heart failure with reduced ejection fraction (HFrEF). Omecamtiv mecarbil stimulates cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that results in contraction of the heart. It is designed to improve cardiac muscle performance, potentially helping patients preserve cardiac function and avoid hospitalizations. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption.

Heart Failure With Reduced Ejection Fraction: Therapeutic Assessment

This segment of the report provides insights about the different Heart Failure With Reduced Ejection Fraction drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Heart Failure With Reduced Ejection Fraction

There are approx. 12+ key companies which are developing the therapies for Heart Failure With Reduced Ejection Fraction. The companies which have their Heart Failure With Reduced Ejection Fraction drug candidates in the most advanced stage, i.e. phase III include, Cytokinetics.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Heart Failure With Reduced Ejection Fraction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart Failure With Reduced Ejection Fraction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure With Reduced Ejection Fraction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure With Reduced Ejection Fraction drugs.

Heart Failure With Reduced Ejection Fraction Report Insights

• Heart Failure With Reduced Ejection Fraction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Heart Failure With Reduced Ejection Fraction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Heart Failure With Reduced Ejection Fraction drugs?
• How many Heart Failure With Reduced Ejection Fraction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure With Reduced Ejection Fraction?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Heart Failure With Reduced Ejection Fraction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Heart Failure With Reduced Ejection Fraction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ionis Pharmaceuticals
• Cytokinetics
• Salubris Biotherapeutics Inc
• MYK-491
• Stealth BioTherapeutics Inc.
• PhaseBio Pharmaceuticals Inc.
• AstraZeneca
• Sardocor Corp.
• Berlin Cures GmbH
• Innolife Co., Ltd.
• Bayer
• Zensun Sci. & Tech. Co., Ltd.
• Olatec Therapeutics LLC
• Intra-Cellular Therapies, Inc.
• Asklepios Biopharmaceutical, Inc.

Key Products

• IONIS-AGT-LRx
• Omecamtiv mecarbil
• JK07
• MYK-491
• Elamipretide
• PB1046
• AZD3427
• SRD-001
• BC 007
• INL1
• BAY 1753011
• Recombinant human Neuregulin
• Dapansutrile
• ITI-214
• NAN-101

This product will be delivered within 2 business days.